MacroGenics, Inc. – Product Pipeline Review

Global Markets Direct’s, ‘MacroGenics, Inc. – Product Pipeline Review – 2016’, provides an overview of the MacroGenics, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by MacroGenics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of MacroGenics, Inc.

The report provides overview of MacroGenics, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses MacroGenics, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features MacroGenics, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate MacroGenics, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for MacroGenics, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding MacroGenics, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

MacroGenics, Inc. Snapshot 6

MacroGenics, Inc. Overview 6

Key Information 6

Key Facts 6

MacroGenics, Inc. - Research and Development Overview 7

Key Therapeutic Areas 7

MacroGenics, Inc. - Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products - Monotherapy 12

Pipeline Products - Partnered Products 13

Partnered Products/Combination Treatment Modalities 14

Pipeline Products - Out-Licensed Products 15

Out-Licensed Products/Combination Treatment Modalities 16

MacroGenics, Inc. - Pipeline Products Glance 17

MacroGenics, Inc. - Late Stage Pipeline Products 17

Phase III Products/Combination Treatment Modalities 17

MacroGenics, Inc. - Clinical Stage Pipeline Products 18

Phase II Products/Combination Treatment Modalities 18

Phase I Products/Combination Treatment Modalities 19

MacroGenics, Inc. - Early Stage Pipeline Products 20

Preclinical Products/Combination Treatment Modalities 20

MacroGenics, Inc. - Drug Profiles 21

margetuximab 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

teplizumab 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

enoblituzumab 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

MGD-006 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

MGD-007 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

MGD-009 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

MGD-010 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

MGA-012 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

MGD-013 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

MGD-014 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Monoclonal Antibodies to Target DR5 for Oncology 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Monoclonal Antibodies to Target EphA2 and CD3 for Breast Cancer 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Monoclonal Antibodies to Target IL13Ralpha2 and CD3 for Melanoma, Glioblastoma Multiforme and Medulloblastoma 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Monoclonal Antibodies to Target ROR1 and CD3 for Oncology 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Monoclonal Antibody Conjugate to Target B7-H3 for Oncology 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

MacroGenics, Inc. - Pipeline Analysis 41

MacroGenics, Inc. - Pipeline Products by Target 41

MacroGenics, Inc. - Pipeline Products by Route of Administration 43

MacroGenics, Inc. - Pipeline Products by Molecule Type 44

MacroGenics, Inc. - Pipeline Products by Mechanism of Action 45

MacroGenics, Inc. - Recent Pipeline Updates 47

MacroGenics, Inc. - Dormant Projects 54

MacroGenics, Inc. - Company Statement 55

MacroGenics, Inc. - Locations And Subsidiaries 58

Head Office 58

Other Locations & Subsidiaries 58

Appendix 59

Methodology 59

Coverage 59

Secondary Research 59

Primary Research 59

Expert Panel Validation 59

Contact Us 59

Disclaimer 60

List of Tables

List of Tables

MacroGenics, Inc., Key Information 6

MacroGenics, Inc., Key Facts 6

MacroGenics, Inc. – Pipeline by Indication, 2016 8

MacroGenics, Inc. – Pipeline by Stage of Development, 2016 11

MacroGenics, Inc. – Monotherapy Products in Pipeline, 2016 12

MacroGenics, Inc. – Partnered Products in Pipeline, 2016 13

MacroGenics, Inc. – Partnered Products/ Combination Treatment Modalities, 2016 14

MacroGenics, Inc. – Out-Licensed Products in Pipeline, 2016 15

MacroGenics, Inc. – Out-Licensed Products/ Combination Treatment Modalities, 2016 16

MacroGenics, Inc. – Phase III, 2016 17

MacroGenics, Inc. – Phase II, 2016 18

MacroGenics, Inc. – Phase I, 2016 19

MacroGenics, Inc. – Preclinical, 2016 20

MacroGenics, Inc. – Pipeline by Target, 2016 42

MacroGenics, Inc. – Pipeline by Route of Administration, 2016 43

MacroGenics, Inc. – Pipeline by Molecule Type, 2016 44

MacroGenics, Inc. – Pipeline Products by Mechanism of Action, 2016 46

MacroGenics, Inc. – Recent Pipeline Updates, 2016 47

MacroGenics, Inc. – Dormant Developmental Projects,2016 54

MacroGenics, Inc., Other Locations 58

MacroGenics, Inc., Subsidiaries 58

List of Figures

List of Figures

MacroGenics, Inc. – Pipeline by Top 10 Indication, 2016 8

MacroGenics, Inc. – Pipeline by Stage of Development, 2016 11

MacroGenics, Inc. – Monotherapy Products in Pipeline, 2016 12

MacroGenics, Inc. – Partnered Products in Pipeline, 2016 13

MacroGenics, Inc. – Out-Licensed Products in Pipeline, 2016 15

MacroGenics, Inc. – Pipeline by Top 10 Target, 2016 41

MacroGenics, Inc. – Pipeline by Route of Administration, 2016 43

MacroGenics, Inc. – Pipeline by Molecule Type, 2016 44

MacroGenics, Inc. – Pipeline Products by Top 10 Mechanism of Action, 2016 45

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports